Pierrel Past Earnings Performance

Past criteria checks 4/6

Pierrel has been growing earnings at an average annual rate of 7.3%, while the Pharmaceuticals industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 4.4% per year. Pierrel's return on equity is 12.1%, and it has net margins of 11.5%.

Key information

7.3%

Earnings growth rate

-17.0%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate4.4%
Return on equity12.1%
Net Margin11.5%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Pierrel makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2FJ0 Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2327370
31 Mar 2325170
31 Dec 2224170
30 Sep 2225170
30 Jun 2224270
31 Mar 2223370
31 Dec 2124370
30 Sep 2121360
30 Jun 2119160
31 Mar 2121360
31 Dec 2018260
30 Sep 2020360
30 Jun 2023460
31 Mar 2021260
31 Dec 1922260
30 Sep 1922160
30 Jun 1921160
31 Mar 1921160
31 Dec 1820160
30 Sep 1821260
30 Jun 1820260
31 Mar 1819050
31 Dec 1717-350
30 Sep 1715-850
30 Jun 1714-950
31 Mar 1714-850
31 Dec 1615-650
30 Sep 1614-260
30 Jun 1614-160
31 Mar 1615060
31 Dec 1516060
30 Sep 15510-20
30 Jun 158600
31 Mar 1513030
31 Dec 1415-260
30 Sep 1430-16170
30 Jun 1429-16170
31 Mar 1429-12170
31 Dec 1330-13170
30 Sep 1330-14180
30 Jun 1336-12180
31 Mar 1340-13190

Quality Earnings: 2FJ0 has a large one-off gain of €741.2K impacting its last 12 months of financial results to 30th June, 2023.

Growing Profit Margin: 2FJ0's current net profit margins (11.5%) are higher than last year (7.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2FJ0 has become profitable over the past 5 years, growing earnings by 7.3% per year.

Accelerating Growth: 2FJ0's earnings growth over the past year (75.3%) exceeds its 5-year average (7.3% per year).

Earnings vs Industry: 2FJ0 earnings growth over the past year (75.3%) exceeded the Pharmaceuticals industry 4.6%.


Return on Equity

High ROE: 2FJ0's Return on Equity (12.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies